Compugen Ltd.'s (CGEN) preliminary Phase 1 readout last November from its COM-701 (anti-PVRIG antibody) all-comers dose-escalation trial was very encouraging. Compugen is proving out the value and capability of its proprietary computational drug discovery platform with 3 of its drugs internally discovered now in Phase 1 clinical trials, as well as collaboration and partnership agreements with major pharmaceutical companies Bristol-Myers, Bayer and AstraZeneca in addition to research collaborations with Johns Hopkins University and Mt. Sinai Hospital in New York. There are numerous upcoming catalysts in 2020 and 2021 described below.
This article updates